Steward Partners Investment Advisory LLC raised its position in CorMedix Inc. (NYSEAMERICAN:CRMD) by 69.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 64,778 shares of the biotechnology company’s stock after buying an additional 26,500 shares during the period. Steward Partners Investment Advisory LLC owned about 0.27% of CorMedix worth $581,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the stock. Wealthstreet Investment Advisors LLC boosted its holdings in CorMedix by 14.0% in the 2nd quarter. Wealthstreet Investment Advisors LLC now owns 16,240 shares of the biotechnology company’s stock worth $146,000 after buying an additional 2,000 shares during the last quarter. WINTON GROUP Ltd acquired a new position in shares of CorMedix during the 2nd quarter worth approximately $90,000. EAM Global Investors LLC acquired a new position in shares of CorMedix during the 1st quarter worth approximately $940,000. Catalyst Capital Advisors LLC acquired a new position in shares of CorMedix during the 1st quarter worth approximately $386,000. Finally, Essex Financial Services Inc. acquired a new position in shares of CorMedix during the 1st quarter worth approximately $95,000.
Several brokerages have recently weighed in on CRMD. Zacks Investment Research cut CorMedix from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 30th. TheStreet upgraded CorMedix from a “d+” rating to a “c-” rating in a report on Friday, August 2nd. Finally, HC Wainwright set a $14.00 target price on CorMedix and gave the stock a “buy” rating in a report on Tuesday, May 28th.
CorMedix (NYSEAMERICAN:CRMD) last released its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.07. The firm had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.06 million.
In other news, Director Janet Dillione purchased 11,144 shares of CorMedix stock in a transaction dated Wednesday, May 15th. The shares were purchased at an average price of $6.74 per share, with a total value of $75,110.56. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
CorMedix Company Profile
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Read More: Oversold
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.